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Abstract : A 71-year-old man with a right lower abdominal quadrant epithelial 
tumor developed gradually worsening lumbago and dysbasia.  He became comatose 
and was admitted to our hospital.  He had swelling of the left axillary lymph 
nodes and necrosis of the 4.0-cm diameter abdominal tumor, which infiltrated 
the subcutaneous tissues.  He was hypercalcemic （16.7 mg / dl）, and had elevated 
levels of soluble interleukin-2 receptor （24,090 U / ml） and parathyroid hormone-
related protein （5.4 pmol / l）.  Computerized tomography （CT） showed left axillary 
lymphadenopathy, splenomegaly, and a right abdominal-wall mass that was described 
as anaplastic large cell lymphoma upon pathology.  Brain radiography and CT 
revealed multiple lesions infiltrating the cranium.  Magnetic resonance imaging 
showed diffuse low signal intensity throughout the vertebral spine.  The patient 
was diagnosed with anaplastic lymphoma kinase （ALK）-negative anaplastic large 
cell lymphoma with hypercalcemia.  Fluid replacement and drug therapies including 
calcitonin had no effect on the hypercalcemia or the coma.  The patient’s serum 
calcium concentration decreased after hemodialysis （calcium dialysate concentra-
tion, 5 mg / dl） and subsequent zoledronic acid hydrate therapy.  His consciousness 
improved by the fth day of treatment.  This rare case of hypercalcemia in ALK-
negative anaplastic large cell lymphoma improved with combined medical and 
hemodialysis therapy.
Key words : hypercalcemia of malignancy, coma, hemodialysis, anaplastic large cell 
lymphoma, ALK negative
Introduction
　There are many cerebral and systemic diseases capable of causing coma.  The cerebral causes 
include cerebrovascular disease, brain tumor, brain damage, encephalitis, and meningitis, whereas 
the systemic causes include hypothermia, hypoxemia, sepsis, electrolyte abnormalities, glucose 
metabolism disorders, endocrine diseases, and drug intoxication.  Hypercalcemia is an electrolyte 
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abnormality that induces coma by interfering with nerve impulse transmission.  If medical 
treatment is delayed or the hypercalcemia is prolonged, then the condition can become life-
threatening.  It is crucial to rapidly and markedly decrease the patient’s serum calcium level.  If 
the usual medical treatments fail to produce a rapid effect, then combining medical therapy with 
hemodialysis is the treatment of choice 1）.
　Hypercalcemia is common in patients with malignancy and occurs in approximately 20 ～
30％ of cases 2）.  The primarily cause of hypercalcemia is increased bone resorption with the 
subsequent release of calcium.  There have been no previous reports of hypercalcemia occurring 
in patients with anaplastic large cell lymphoma （ALCL）.  Here, we report a patient with the 
rare combination of hypercalcemia and anaplastic lymphoma kinase （ALK）-negative ALCL. 
This patient recovered well from hypercalcemia-induced coma following combined medical and 
hemodialysis therapy.
Case Report
　A 71-year-old Japanese man was diagnosed with an epithelial tumor in the right lower 
abdominal quadrant in May 2011.  He developed gradually worsening lumbago and dysbasia 
in April 2012, and in May 2012 he became comatose （Glasgow Coma Scale score, 10 points） 
and was admitted to our hospital.  His past history was relevant for hypertension because his 
family history revealed gastric cancer in his brother and pancreatic cancer in his sister.  His 
blood pressure at admission was 118 / 60 mm Hg, his body temperature was 36.8℃, and his 
pulse rate was 66 beats per minute.  His conjunctiva were neither pale nor jaundiced.  His 
breath sounds and heartbeat were normal.  The left axillary lymph nodes were swollen, but 
no other lymphadenopathy was detected.  A 4.0-cm diameter epithelial tumor with necrosis 
and the subcutaneous infiltration was identified in the right lower abdominal quadrant （Fig. 
1）.  The patient’s muscle strength was level 4 on the Manual Muscle Test scale and there 
Fig. 1.　The epithelial tumor was in the 
right lower abdominal quadrant :  
the tumor was 4.0 cm in diameter, 
with necrosis and subcutaneous 
infiltration.
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was no paralysis of the limbs.  The laboratory data are shown in Table 1 and the notable 
findings were : hypercalcemia （16.7 mg / dl）, elevated levels of soluble interleukin-2 receptor 
（sIL-2R） （24,090 U / ml） and parathyroid hormone-related protein （PTHrP） （5.4 pmol / l）, 
whole parathyroid hormone and active vitamin D levels were not elevated.  The patient 
had thrombocytopenia and the results for immunoelectrophoresis analysis were negative for 
Table 1.  Laboratory ndings on admission
Blood cell count Serological test
WBC /μL 23 × 102 IgG mg / dL 1752
  RBC /μL 532 × 104 IgA mg / dL 416
  Hb g / dL 17.0 IgM mg / dL 233
  Plt /μL 10.4 × 104 whole PTH pmol / L ＜ 6
PTHrP pmol / L 5.4
Blood chemistry 1-25（OH）2VitD3 pg / mL 25
  TP g / dL 7.4 PSA ng / mL 0.167
  Alb g / dL 3.1 CEA ng / mL 1.5
  UN mg / dL 38 SCC ng / mL 0.2
  Cr mg / dL 0.9 SLX U / mL 31.1
  UA mg / dL 18.4 NSE ng / mL 122.5
  Na mEq / L 142 cytokeratin 19 ng / mL 1.8
  K mEq / L 3.8 AFP ng / mL 3
  Cl mEq / L 90 sIL-2R U / mL 24090
  Ca mg / dL 16.7 M protein -
  P mg / dL 3.4 Bence-Jones ptotein -
  AST U / L 82 HTLV-1 antibody -
  ALT U / L 62
  γ-GTP U / L 70 Urinalysis
  ALP U / L 275   Protein -
  LDH U / L 369   Occut blood 1＋
  Glu mg / dL 131
  hsCRP mg / dL 1.8
WBC＝white blood cell count ; RBC＝red blood cell ; Hb＝hemoglo-
bin ; Plt＝blood platelet ; TP＝ total protein ; Alb＝albumin ; UN＝
blood urea nitrogen ; Cr＝creatinine ; UA＝uric acid ; Na＝sodium ; K
＝potassium ; Cl＝chloride ; Ca＝calcium ; iP＝ inorganic phosphorus ; 
AST＝aspartate aminotransferase ; ALT＝alanine aminotransferase ; γ- 
GTP＝γ-glutamyltranspeptidase ; ALP＝alkaline phosphatase ; LDH
＝ lactate dehydrogenase ; Glu＝glucose ; hsCRP＝high sensitivity 
C-reactive protein ; IgG＝ immunoglobulin G ; IgA＝ immunoglobulin A ; 
IgM＝ immunoglobulin M ; whole PTH＝whole parathyroid hormone ; 
PTHrP＝parathyroid hormone-related protein ; 1-25（OH）2VitD3＝
1,25-dihydroxyvitamin D3 ; PSA＝prostate-specific antigen ; CEA＝
carcinoembryonic antigen ; SCC＝squamous cell carcinoma antigen ; SLX
＝sialyl Lewis X-i antigen ; NSE＝neuron-specific enolase ; AFP＝
alpha-fetoprotein ; sIL-2R＝soluble interleukin-2 receptor ; M protein＝
monoclonal protein ; ATLA＝adult T-cell leukemia-associated antigen
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monoclonal immunoglobulin and Bence-Jones protein in blood and urine.  The test for anti-adult 
T-cell leukemia-associated antigen antibody yielded a negative result.  Plain chest radiography 
did not show hilar lymphadenopathy or any other abnormalities.  An electrocardiogram 
showed normal sinus rhythm without a prolonged Q-T interval （QTc interval, 436 ms）.  Chest 
computerized tomography （CT） showed left axillary lymphadenopathy （Fig. 2）.  Abdominal CT 
revealed splenomegaly and a right abdominal wall mass of slightly higher density than muscle 
（image not shown）.  Brain radiography and brain CT for bone condition revealed multiple 
infiltrating lesions in the cranial bones （Fig. 3）.  T1-weighted magnetic resonance imaging showed 
diffuse low signal intensity throughout the vertebral spine （Fig. 4）.  Based on these findings, we 
diagnosed clinically malignant lymphoma with hypercalcemia.
Fig. 2.　Chest computed tomography （CT） shows left 
axillary lymphadenopathy is indicated by the arrow.
Fig. 3.　Brain CT （bone window）shows 
multiple infiltrating lesions in 
the cranial bones are indi cated 
by the arrows.
Fig. 4.　T1-weighted magnetic res o-
nance imaging shows diffuse 
low signal intensity throughout 
the vertebral spine.
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　A biopsy of the right lower quadrant tumor was obtained, and treatment was initiated while 
awaiting the biopsy results.  Fluids were replaced with 3 l of isotonic saline solution per day, 
and intravenous furosemide of 40 mg with 80 units / day of a calcitonin derivative, elcatonin, 
were administered intramuscularly to treat the hypercalcemia.  Hemodialysis was initiated on 
the second hospital day, after no rapid effect of these treatments was observed and the patient 
had developed tachycardia of 150 beats / min.  The dialysis time was 4 h, with a blood flow 
of 150 ml / min and a dialysate flow rate of 500 ml / min.  The membrane area was 1.5 m2 
and the calcium concentration of the dialysate was 5 mg / dl.  On the following day, 4 mg of 
the bisphosphonate, zoledronic acid hydrate, was administrated by intravenous injection.  The 
patient’s serum calcium concentration levels decreased after hemodialysis.  His total calcium level 
decreased from 16.7 mg / dl to 9.3 mg / dl, and ionized calcium level decreased from 11.0 mg /
dl to 5.5 mg / dl.  On the fifth day in hospital, his consciousness had improved and his medical 
condition was stable.  On the eighth day in hospital, he was transferred to another hospital to 
begin chemotherapy （Fig. 5）.
　A review of the biopsy results revealed a dense dermal infiltrate of atypical lymphocytes in 
the hematoxylin and eosin-stained specimens.  The subcutaneous adipose tissue was infiltrated 
by diffuse atypical lymphocytes.  These cells had abundant cytoplasm and horseshoe-shaped 
nuclei, with prominent multiple or single nucleoli （Fig. 6）.  Immunostained specimens showed 
numerous neoplastic cells that stained positive for CD30 （Fig. 7A）, and were negative for the 
ALK protein （Fig. 7B）.  This staining pattern is indicative of ALCL.  The neoplastic cells 
stained positive for CD2, CD5, CD56 and epithelial membrane antigen （EMA）, and were 
negative for CD3, CD4 and CD8.  The final diagnosis for the patient was ALK-negative ALCL 
with hypercalcemia.
Fig. 5.　Clinical course. Total calcium levels are indicated 
by diamond blocks and ionized calcium levels 
are indicated by square blocks. HD, hemodialysis.
Fig. 6.　Hematoxylin and eosin stain of the dermis   
reveals a dense infiltrate of atypical lympho-
cytes.
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Discussion
　ALCL is a type of non-Hodgkin lymphoma （NHL） that represents approximately 2％ of 
NHL cases in adults 3）.  At present, malignant lymphomas are classified according to the fourth 
edition of the World Health Organization Classification of Tumours of Haematopoietic and 
Lymphoid Tissues 4）.  The type of disease is determined by cell morphology, origin of tumor cells, 
genetic abnormalities, chromosomal aberrations, and clinical characteristics.
　ALCL is a T-cell lymphoma that consists of large lymphoid cells with abundant cytoplasm, 
horseshoe-shaped nuclei, and strong CD30 expression.  The tumor is classified as primary 
cutaneous ALCL if it is confined to the skin in patients with no pre-existing lymphoproliferative 
disorder.  ALCL can also be classified as primary systemic ALCL, which occurs in patients with 
systemic disease, and is further classified into ALK-positive ALCL and ALK-negative ALCL. 
Several retrospective studies have found that patients with ALK-negative ALCL have worse 
overall survival than those with ALK-positive tumors 5-7）.  We diagnosed our patient with ALK-
negative ALCL based on the presence of axillary lymphadenopathy, splenomegaly, skin tumor, 
bone infiltration, and ALK-negative status.
　Laboratory investigations have found that 40％ of patients with primary systemic ALCL have 
an elevated lactate dehydrogenase level, 30％ have anemia, and 10％ exhibit thrombocytopenia. 
The skin is the most common site of extranodal disease （25％）, whereas other sites include the 
gastrointestinal tract, breast, spleen, liver, and bone 6, 8）.  Our patient had thrombocytopenia and 
presented with extranodal disease of the skin, spleen, and bone.
　Primary hyperparathyroidism and malignancy are the most common causes of hypercalcemia, 
and account for more than 90％ of cases 9, 10）.  Moreover, hematologic malignancies account 
for 15％ of malignancy-associated hypercalcemia cases 11）.  Several types of NHL are prone to 
hypercalcemia, including adult T-cell leukemia / lymphoma and diffuse large B-cell lymphoma with 
hypercalcemia, but we could not find any reports of this complication in ALCL.
　Hypercalcemia in patients with cancer primarily results from increased bone resorption and 
Fig. 7.　Immunostaining of the dermis
A : Numerous neoplastic cells stained positive for CD30.
B : Numerous neoplastic cells stained negative for anaplastic lymphoma kinase protein.
A B
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the subsequent release of calcium into the circulation.  There are three major mechanisms for 
tumor-derived hypercalcemia : osteolytic metastases causing local release of cytokines, otherwise 
known as local osteolytic hypercalcemia （LOH）; tumor secretion of PTHrP, also termed humoral 
hypercalcemia of malignancy （HHM）; and tumor production of 1,25-dihydroxyvitamin D3 （active 
vitamin D）2, 12-14）.  Hypercalcemia of malignancy by LOH is less common with NHL 2, 13）, 
whereas HHM and tumor production of active vitamin D are more commonly noted 9, 13, 15）. 
Initially, we hypothesized that the hypercalcemia in this patient resulted from HHM, given his 
elevated levels of PTHrP and low levels of active vitamin D.  The tumor infiltration of bone 
suggests that LOH coexisted with HHM, which may have caused the notable hypercalcemia.
　Typically, the first intervention in a patient with hypercalcemia is fluid replacement with 
isotonic saline solution.  This treatment needs to be supplemented in most cases with 
medications, including calcitonin and bisphosphonates, because its effect is transient.  Calcitonin is 
a calcium regulatory hormone that strongly inhibits the bone-resorbing activity of osteoclasts 16）. 
Bisphosphonates bind to exposed hydroxyapatite on bone surfaces, particularly those undergoing 
active resorption.  When osteoclasts begin to resorb bone impregnated with bisphosphonates, they 
become impaired because of the resulting release of the bisphosphonate 17-20）.  Glucocorticoids 
inhibit the production by the tumor of locally active cytokines that have direct osteolytic 
effects 1, 2, 11, 12）.  If the coexistence of LOH were definitely established then the curative effect 
would be higher by the use of combination steroid therapy.
　Hemodialysis with low-calcium or calcium-free dialysate is recommended in cases where 
fluid replacement with isotonic saline and medical therapy does not affect the hypercalcemia 1）. 
It should also be used if the patient has renal failure or is in a coma 1）.  As neither the 
hypercalcemia nor the coma in this patient improved with the initial treatment, hemodialysis 
with a low-calcium dialysate was initiated.  Prompt control of serum calcium levels and 
treatment of the underlying disease are important for the patient’s prognosis in the treatment 
of hypercalcemia of malignancy 21）.  We suggest that the control of this patient’s calcium levels 
with hemodialysis contributed to the positive outcome.  Both low-calcium and calcium-free 
dialysate solutions are used in hemodialysis for hypercalcemia 22-26）.  It should be noted that 
calcium-free hemodialysis solutions are responsible for the major adverse event of hypotension 
in 35％ of sessions 23）.  This complication is probably due to a rapid decline in calcium level 
that results in the elimination of the vasoconstrictor effect of the mineral.  In Japan, most 
commercially available dialysates contain calcium levels of 5.0 to 7.0 mg / dl.  We selected the 
lower dialysate concentration, and the patient’s blood pressure after hemodialysis decreased from 
155 mm Hg to 120 mm Hg, which was mild.  The most effective concentration for hemodialysis 
treatment for hypercalcemia has not yet been established and further studies of dialysate calcium 
concentrations are needed.
　In summary, we report the rare complication of hypercalcemia in a patient with ALK-negative 
ALCL.  The patient recovered well from the coma of hypercalcemia with malignancy, after 
combined hemodialysis and medical therapy.
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